<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127891">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02087475</url>
  </required_header>
  <id_info>
    <org_study_id>SAH 5010 CRC</org_study_id>
    <nct_id>NCT02087475</nct_id>
  </id_info>
  <brief_title>Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin</brief_title>
  <official_title>Randomized Open-label Phase III Study Comparing Perioperative FOLFIRI Versus Adjuvant FOLFIRI in Resectable Advanced Colorectal Cancer Failed to Oxaliplatin-containing Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer (CRC) is one of the most leading causes of cancer death in China. Although
      multiple treatment modalities including surgery, radiotherapy and chemotherapy have been
      developed, the prognosis of advanced CRC still remains poor. While around 30% of resectable
      advanced CRC could be cured. This study is designed to compare perioperative FOLFIRI versus
      adjuvant FOLFIRI in resectable advanced CRC who exposed to oxaliplatin in open-label, phase
      III mode.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progress Free Survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 Years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 Resection Rate</measure>
    <time_frame>6 Month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 Year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events grade that greater than 3 is considered secondary endpoint, according to the Common Terminology Criteria for Adverse Events Version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality</measure>
    <time_frame>3 Years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>EORTC QoL Questionaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Effects of Chemotherapy</condition>
  <condition>Surgery</condition>
  <condition>Metastasis</condition>
  <condition>Local Neoplasm Recurrence</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant therapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRI * 6 cycles +/- radiotherapy -&gt; surgery -&gt; FOLFIRI * 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant therapy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery -&gt; FOLFIRI * 12 cycles +/- radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Neoadjuvant therapy arm</arm_group_label>
    <arm_group_label>Adjuvant therapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <arm_group_label>Neoadjuvant therapy arm</arm_group_label>
    <arm_group_label>Adjuvant therapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Local radiotherapy</intervention_name>
    <arm_group_label>Neoadjuvant therapy arm</arm_group_label>
    <arm_group_label>Adjuvant therapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>R0 resection</intervention_name>
    <arm_group_label>Neoadjuvant therapy arm</arm_group_label>
    <arm_group_label>Adjuvant therapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age:18-80

          -  ECOG score: 0 or 1

          -  Histological confirmed of Colorectal Adenocarcinoma

          -  History of exposure to oxaliplatin

          -  With local recurrent or metastatic focus

          -  Tumor resectable confirmed by at less 3 hepatobiliary surgeon

          -  Informed content acquired

        Exclusion Criteria:

          -  History of Exposure to Irinotecan

          -  Received surgery in recently 4 weeks or did not recover from surgery

          -  Other history of cancer in recent 5 years

          -  Fluorouracil allergy or dihydropyrimidine dehydrogenase defect

          -  Women with potential pregnancy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Lan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Xiao, MD</last_name>
    <phone>+8613711114566</phone>
    <email>xiao_jian@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The 6th Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Xiao, MD</last_name>
      <phone>+8613711114566</phone>
      <email>xiao_jian@139.com</email>
    </contact>
    <investigator>
      <last_name>Jian Xiao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Lan Ping</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasm Recurrence, Local</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
